| Literature DB >> 17683616 |
Dominik Domanski1, Caren C Helbing.
Abstract
BACKGROUND: Thyroid hormones (THs) are vital in the maintenance of homeostasis and in the control of development. One postembryonic developmental process that is principally regulated by THs is amphibian metamorphosis. This process has been intensively studied at the genomic level yet very little information at the proteomic level exists. In addition, there is increasing evidence that changes in the phosphoproteome influence TH action.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17683616 PMCID: PMC2025591 DOI: 10.1186/1471-213X-7-94
Source DB: PubMed Journal: BMC Dev Biol ISSN: 1471-213X Impact factor: 1.978
Figure 1Subcellular fractionation of the tail fin proteome. (A) Fractionation of tail fin cells into subcellular compartments and subsequent treatments of those fractions. Two different extraction procedures, based on differential centrifugation, were developed to generate the nuclear and the cytoplasmic/mitochondrial/microsomal fractions. (B) SDS-PAGE shows the successful fractionation of the total tail fin proteome into the cytosolic (Cytos), mitochondrial (Mito), microsomal (Micros), and nuclear (Nucl) fractions. Relative molecular weights of protein standards are indicated in kDa. (C) Immunoblot of the gel in (B) for the mitochondrial marker, cytochrome c (arrow) showing the enrichment of mitochondria in the expected fraction. (D) Immunoblot of the gel in (B) for the nuclear markers, lamin B1 and B2 (double arrow) showing the enrichment of nuclei in the expected fraction.
Figure 2Anion-exchange HPLC fractionation of the cytosolic fraction. (A) The cytosolic fraction was further fractionated using an anion-exchange column (Accell QMA) with a step-gradient of increasing concentrations of ammonium bicarbonate (straight lines). The concentrations are indicated on each step while absorbance was measured at 280 nm indicating the protein yield of each fraction. (B) The Coomassie blue-stained SDS-PAGE gel shows the fractionation of the cytosolic sample (total) with the lanes corresponding to the cytosolic fractions below the peaks of the HPLC chromatogram. Note the resulting enrichment of certain protein bands. Relative molecular weights of protein standards are indicated in kDa.
Figure 32D gel analyses of the nuclear, mitochondrial and microsomal fractions. Proteins from the nuclear, mitochondrial and microsomal fractions were separated by 2D-PAGE according to molecular weight and pI point. Total proteins were detected by colloidal Coomassie stain while phosphoproteins were detected in the same gel using the ProQ Diamond phosphoprotein-specific stain. Relative molecular weights of protein standards are indicated in kDa.
Figure 42D gel analysis of the anion-exchange HPLC cytosolic fractions. Proteins from each of the fractions resulting from the anion-exchange HPLC of the cytosolic sample were separated by 2D-PAGE according to molecular weight and pI point. The 40 mM fraction is the unbound protein fraction, while the subsequent fractions are proteins eluted by the increasing ammonium bicarbonate concentration step-gradients. Total proteins were detected by colloidal Coomassie stain while phosphoproteins were detected in the same gel using the ProQ Diamond phosphoprotein-specific stain. Relative molecular weights of protein standards are indicated in kDa.
Figure 5Identification of a novel . (A) 2D gel regions of the 340 mM cytosolic, microsomal, mitochondrial, and nuclear fractions show the increase of a protein spot at ~24 kDa and pI ~5 due to T3 treatment at 48 h. The corresponding gel region, stained with a phosphoprotein stain, is shown for the nuclear fraction revealing additional changes in the phosphoproteome. The white arrows indicate the spot identified as a novel type I keratin RLK I fragment in the T3 samples (see Table 1). In the phosphoprotein gel, the white arrow indicates a possible phosphorylated form of the keratin fragment. The gray arrows indicate an additional unidentified protein and phosphoproteins that are altered upon T3 treatment. Relative molecular weights of protein standards are indicated in kDa. (B) Spot density measurements (in arbitrary values) are graphed for the corresponding 2D gels on the left. The white bar represents the control while the gray bar represents the T3 treatment. Error bars represent the standard error of the mean from three independent controls and three independent T3 samples. Significance is indicated by an asterisk for p < 0.01 and by a black dot for p < 0.04 (ANOVA). The values adjacent to the gray bars represent the fold increase due to T3. In the nuclear fraction (k) represents the keratin spot, while (s1) represents an additional protein spot observed to be increased, and (s2) and (s3) represent two phosphoproteins that were increased due to T3 treatment. Spot density measurements were normalized between the gels with the β-actin protein spot.
MS analysis of protein spot identified to be a type I keratin fragment
| 807.4 | LAADDFR | Yes | 84/89 | LAADDFR |
| 809.4 | LASYLDK | Yes | 100/na | LASYL |
| 991.5 | FENELALR | Yes | 100/98 | FENELALR |
| 1041.6 | LVLQIDNAR | Yes | 100/100 | |
| 1073.6 | ILAATIDNSR | Yes | 100/100 | IL |
| 1079.5 | VLDELTMSR | Yes | 100/74 | VLDELT |
| 1184.6 | YYDIINDLR | - | 96/- | Y |
| 1202.6 | QSVEADINGLR | - | 43/- | QSVE |
| 1224.6 | NHEEELQVAR | - | 73/- | NHEEE |
| 1232.7 | - | Yes | -/100 | LKFENELALR |
| 1301.6 | ALEAANTELELK | - | 93/- | ALEAAN |
1Observed peptide masses resulting from the tryptic digestion of the protein spot, reported as singly charged. 2Peptide sequence information deduced from MS/MS spectra of the corresponding peptides from ESI-QqTOF analysis. The masses of isoleucine are indistinguishable from leucine in MS and therefore L can be I and vice versa. 3Indicates which peptides were additionally observed with MALDI-TOF-TOF analysis. 4Percent confidence for the peptide sequences as reported by PEAKS software for the ESI-QqTOF spectra and by MASCOT for MALDI-TOF-TOF data. 5Highest homology match from protein database searching with the observed peptide sequences to X. laevis type I keratin 47 kD using SPIDER software. Bold lettering indicates differences between the observed and database sequences.
Figure 6RLK I cDNA and derived amino acid sequence and location of MS/MS peptide fragments. The complete nucleotide sequence (lower case) of RLK I cDNA is shown. Underlined nucleotide sequences indicate all the in-frame stop codons, the first methionine codon, and a consensus AATAAA polyadenylation signal. Numbers on the right indicate nucleotide position. Upper case letters indicate the deduced amino acid sequence (single letter code). Boxed sequences indicate tryptic peptides observed in the MS analyses of the RLK I protein spot from the 2D analysis. The underlined VEMDA sequence indicates a consensus caspase cleavage site identified in human type I keratins with the black inverted-triangle indicating the cleavage site. Black dots adjacent to two serine residues indicate possible phosphorylation sites based on those found in human K18 at Ser33 and Ser52 (here Ser34 and Ser52). Numbers on the left indicate amino acid position.
Figure 7Multiple sequence alignment of the derived amino acid sequence of RLK I. The derived amino acid sequence of RLK I [GenBank: EF156435] was aligned with the X. laevis type I keratin 47 kDa protein [GenBank: P05781] (Xl 47 kDa), a partial R. catesbeiana adult type I keratin RAK [GenBank: BAB47394.1] (RAK), the human type I keratin K19 [GenBank: NP_002267.2] (h K19), and the R. catesbeiana larval type II keratin RLK [GenBank: BAB47395] (RLK II) sequences. Gaps that were inserted for optimal alignment are indicated by a dash. Identical amino acids are shaded. Numbers indicate amino acid position for each sequence. The alignment was done using ClustalW software [22].
Figure 8Changes in transcript and protein fragment levels of RLK I in the tail fin. (A) Fold change in steady-state levels of the keratin transcript relative to time-matched controls after 100 nM T3 exposure for 24, 48 and 72 h. White bars represent controls and gray bars represent T3 treatments. Error bars represent the standard error of the mean (n = 4 for all treatments). Significance is indicated by an asterisk for p < 0.03 (Mann-Whitney U). (B) Fold change in steady-state levels of the keratin transcript at different stages of natural metamorphosis relative to premetamorphic TK stage VI-VIII [31]. Error bars represent the standard error of the mean (n = 4 for all treatments). Significance is indicated by a double asterisk for p < 0.002 (Mann-Whitney U). (C) Immunobloting microsomal fraction samples using anti-pan-cytokeratin antibody reveals the appearance of the keratin fragment (25 kDa) and a concomitant loss of keratin at 50 kDa due to 10 nM T3 treatment. Relative molecular weights of protein standards are indicated in kDa. Shown is a representative of two independent experiments.
Figure 9Phosphorylation changes in γ-interferon-inducible lysosomal thiol reductase (GILT). (A) Phosphoprotein 2D gel regions of the mitochondrial and microsomal fractions showing the increase in a row of phosphoprotein spots (s1, s2, s3) due to T3 treatment at 48 h, while a corresponding total-protein stained 2D region shows no change in the only detectable protein spot s2 (gray arrows). Relative molecular weights of protein standards are indicated in kDa. (B) Spot density measurements (in arbitrary values) are graphed for the corresponding 2D gels on the left. The white bar represents the control while the gray bar represents the T3 treatment. Error bars represent the standard error of the mean from three independent controls and three independent T3 samples. Significance is indicated by an asterisk for p < 0.01 and by black dot for p < 0.1 (ANOVA). The values adjacent to the gray bars represent the fold increase due to T3. Phosphoprotein spots s1, s2, and s3 increase while the corresponding protein spot s2 does not change. MS analysis of the only detectable protein spot s2 (gray arrow) is indicated in table 2. Spot density measurements were normalized between the gels with the β-actin protein spot.
MS analysis of protein spot identified as GILT
| 1399.8 | (CL)FNLVTELYK | 100 (98) | 1877 | |
| 1405.7 | (TV)LDCVDGDLGNK | 100 (90) | 0.001 | |
MS analysis of the only detectable protein spot s2 (gray arrows in Fig. 9). 1Observed peptide masses resulting from the tryptic digestion of the protein spot s2, reported as singly charged. 2Peptide sequence information deduced from MS/MS spectra of the corresponding peptides from ESI-QqTOF analysis. The masses of isoleucine are indistinguishable from leucine in MS and therefore L can be I and vice versa. 3Percent confidence for the peptide sequences, as reported by PEAKS software for the ESI-QqTOF spectra. 4Highest homology match from protein database searching with the observed peptide sequences to X. tropicalis GILT. Indicates the sequence alignment of the observed peptide to the identified protein (Database) as aligned by BLASTp. The sequence in between indicates the matching and similar (+) amino acids between the two sequences.5From BLASTp alignments.
Figure 10iTRAQ analysis. Two control and two treatment samples were each labeled with one of the four iTRAQ tags as shown. The peptide samples were pooled, fractionated by two dimensions of liquid chromatography (cation-exchange and reverse-phase), and analyzed by MS. The iTRAQ sample was analyzed three times on an ESI-QqTOF mass spectrometer and once on a MALDI-TOF-TOF mass spectrometer. The image shows a sample MS/MS spectrum of a single peptide from which the amino acid sequence is deduced, and in addition, it reveals the four reporter ions (enlarged region) from the iTRAQ tags, in the low-mass region, whose intensity indicates the relative abundance of that peptide in the four samples. The two controls are labeled with tags 114 and 116, and show reporter ions at that m/z, while the two T3 treatment samples are labeled with tags 115 and 117, showing reporters at those m/z. This spectrum reveals an increase in that peptide due to T3.
Summary of results for iTRAQ analysis by ESI-QqTOF
| 7682 | 6249 | 6361 | n/a | |
| 17 | 17 | 21 | ||
| 13 | 16 | 18 | ||
| 8 | 7 | 11 | ||
| 1 | 1 | 2 | ||
The iTRAQ samples were analyzed three times on an ESI-QqTOF mass spectrometer. 1Indicates number of unique spectra shared between the replicate runs. 2Total number of unique spectra recorded per MS analysis run. These overlap by unknown amount: n/a. 3Number of spectra that change by ≥ 1.5 fold due to T3, have good quality reporter tags, and a ratio of the two controls between 0.67 and 1.5. 4Number of spectra for which amino acid sequence could be obtained through manual sequencing. 5Number of spectra for which a protein inference was made with BLASTp. 6Indicates how many spectra were identified using the standard iTRAQ analysis with MASCOT software. 7Number of different proteins identified from the resulting peptides and their change in abundance.
Differentially expressed proteins in the Rana catesbeiana tail fin due to T3-induction as analyzed by iTRAQ
| MGC80395 protein (Sterol regulatory element-binding transcription factor 2) [AAH72922/ | 1.6 | 2949.6 | LTPATVET (frag.) | manual | 136 | |
| Inter-α inhibitor H4 [XP_848765/ | 2.1 | 1789.1 | V(TFE)LVYEEMLK | 90–100 (53) | 0.004 | |
| Hemoglobin α-III chain, larval [P02011/ | 1.5 | 1224.7 | FLSFPQTK (frag.) | manual | Query 1 FLSFPQTK 8 | 5.4 |
| Hemoglobin α-III chain, larval [P02011/ | 1.5 | 1250.8 | FLSFPQTK (frag.) | 100 | Query 1 FLSFPQTK 8 | 5.4 |
| Hemoglobin α-III chain, larval [P02011/ | 1.5 | 2067.0 | YVPHFDLTPGSADLNK | 99 | Query 1 YVPHFDLTPGSADLN 15 | 9 e-05 |
| MGC80107 protein (Biliverdin reductase B) [AAH72790/ | 1.5 | 1904.3 | VISTPDLSHFFLR | 100 | Query 1 VISTPDLSHFFLR 13 | 0.26 |
| Immunoglobulin heavy chain [AAC12909/ | 1.6 | 1237.8 | VVLLPPSPK | 99 | Query 1 VVLLPPSP 8 | 63 |
| Immunoglobulin heavy prechain [CAA33212/ | 2.0 | 1817.9 | SDPDQGFDGTYTVK | manual | Query 1 SDPDQGFDGTYTVK 14 | 52 |
| Immunoglobulin heavy chain constant region [AAC12914/ | 46 | 1391.7 | LNVADWNSGK | 99 | Query 1 LNVA--DWNSGK 10 | 170 |
| Immunoglobulin M heavy chain [AAO37747/ | 1.5 | 2065.0 | FTCTVSHSDLPAPVEK | 95 | Query 1 FTCTVSHSDLPAP 13 | 7 e-04 |
| Immunoglobulin heavy chain variable region [AAP41191/ | 1.6 | 1930.3 | (RKQ)VVEAGGALIK | 100 (92–96) | Query 3 QVVEEAGGALIK 14 | 22 |
| Immunoglobulin heavy prechain [CAA33212/ | 1.6 | 1471.8 | DQGFDGTYTVK | manual | Query 4 FDGTYTVK 11 | 9.2 |
| LOC443721 protein (cathepsin D) [AAH94178/ | 1.7 | 980.5 | AYWQIR | 98 (MALDI) | Query 1 AYWQIR 6 | 42 |
| α-2-macroglobulin [AAY98517/ | 0.67 | 2195.2 | AYVTV(LGD)IMGTALENLDR | 97–100 (41) | Query 1 AYVTVLGDIMGTALENLDR 19 | 1 E-08 |
| Calcium-binding protein p26olf [BAA34388/ | 0.47 | 1312.7 | GNTTSMNFK | manual | Query 1 GNTTSMNFK 9 | 0.57 |
| α1type I collagen [BAA29028/ | 0.52 | 2111.2 | TGPAGAPGQDGRPGPPGPPGAR | manual | Query 1 TGPAGAPGQDGRPGPPGPPGAR 22 | 6 e-12 |
| α1type I collagen [BAA29028/ | 0.52 | 2418.2 | PPGPSGEK (frag.) | 97 | Query 1 PPGPSGEK 8 | 17 |
| Caridac α actin 2 [AAX85445/ | 0.38 | 2244.3 | VAPEEH(PT)LLTEAPLNPK | 93–100 (66) | Query 1 VAPEEHPTLLTEAPLNPK 18 VAPEEHPTLLTEAPLNPK Sbjct 98 VAPEEHPTLLTEAPLNPK 115 | 3 e-09 |
| myosin heavy chain (skeletal muscle MHC-3) [AAD13771/ | 0.39 | 2491.9 | FQAALEEAEASLEHEEAK | manual | Query 1 FQAALEEAEASLEHEEAK 18 FQAALEEAEASLEHEEAK | 8 e-09 |
| Mylpf-prov protein (myosin light chain 2) [AAH41503/ | 0.38 | 2098.2 | NICYVITHGED (frag.) | 100 | Query 1 NICYVITHGED 11 | 0.002 |
| MGC68533 protein (coatomer protein complex, subunit γ) [AAH61661/ | 0.61 | 1491.6 | NAHSLYLAGVFR | 99 (MALDI) | Query 1 NAHSLYLAGVFR 12 | 0.002 |
| Cortactin [NP_005222/ | 0.65 | 1585.9 | YGLFPANYVELR | 98 (MALDI) | Query 1 YGLFPANYVELR 12 YLFPANYVELR | 4 e-04 |
| Triose phosphate isomerase [NP_788764/ | 0.64 | 1711.8 | DIGADWVILGHSER | 100 (MALDI) | Query 1 DIGADWVILGHSER 14 | 7 e-06 |
1Name of protein for the highest scoring match that resulted with the observed peptide sequence using BLASTp (2.2.15) and the NCBI protein database (Oct. 15, 2006) searching all metazoans. The NCBI accession number and the species name for the identified protein are shown. 2Fold change ratios greater then 1.0 indicate a fold increase, and those below 1.0 indicate the reciprocal of fold decrease. The number is the average fold change of two replicate experiments, which consisted of two treatment samples and two control samples. 3Observed mass of the peptide in the MS analysis, modified with the iTRAQ reagent, reported as singly charged. 4Amino acid sequence determined for the observed peptide by manual de novo or automatic de novo by PEAKS software sequencing, or a MASCOT software match. (frag.) indicates that only a partial peptide sequence could be determined. The masses of isoleucine are indistinguishable from leucine in MS and therefore L can be I and vice versa. 5Percent confidence for the peptide sequence as reported by the PEAKS or MASCOT (MALDI) software. (MALDI) indicates that the peptide was identified in the MALDI-TOF-TOF analysis of iTRAQ samples. "manual" indicates that the peptide sequence was obtained manually and no percent confidence can be reported. 6Indicates the sequence alignment of the observed peptide (Query) to the identified protein (Sbjct) as aligned by BLASTp. The sequence in between indicates the matching and similar (+) amino acids between the two sequences. 7From BLASTp alignments.